Brokerages Set Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) PT at $230.56

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) has been given an average rating of “Moderate Buy” by the nineteen research firms that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $241.5294.

A number of research firms have recently commented on JAZZ. Piper Sandler increased their target price on Jazz Pharmaceuticals from $232.00 to $301.00 and gave the company an “overweight” rating in a research report on Friday. Leerink Partners increased their target price on Jazz Pharmaceuticals from $215.00 to $225.00 and gave the company an “outperform” rating in a research report on Wednesday, April 22nd. Robert W. Baird set a $252.00 target price on Jazz Pharmaceuticals in a research report on Wednesday, May 6th. Barclays increased their target price on Jazz Pharmaceuticals from $225.00 to $234.00 and gave the company an “overweight” rating in a research report on Wednesday, May 6th. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of Jazz Pharmaceuticals in a research report on Friday, March 27th.

Insider Buying and Selling

In related news, Director Norbert G. Riedel sold 3,415 shares of the firm’s stock in a transaction on Friday, February 27th. The stock was sold at an average price of $192.00, for a total value of $655,680.00. Following the completion of the sale, the director directly owned 7,024 shares in the company, valued at $1,348,608. This trade represents a 32.71% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Neena M. Patil sold 55,600 shares of the firm’s stock in a transaction on Thursday, February 26th. The stock was sold at an average price of $191.56, for a total value of $10,650,736.00. Following the completion of the sale, the executive vice president owned 56,862 shares of the company’s stock, valued at approximately $10,892,484.72. This represents a 49.44% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 74,015 shares of company stock valued at $14,180,486 over the last 90 days. 4.30% of the stock is currently owned by insiders.

Institutional Trading of Jazz Pharmaceuticals

A number of institutional investors have recently bought and sold shares of JAZZ. Royal Bank of Canada lifted its position in Jazz Pharmaceuticals by 96.5% in the first quarter. Royal Bank of Canada now owns 67,614 shares of the specialty pharmaceutical company’s stock worth $8,394,000 after buying an additional 33,210 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in shares of Jazz Pharmaceuticals by 147.7% during the first quarter. Goldman Sachs Group Inc. now owns 351,609 shares of the specialty pharmaceutical company’s stock worth $43,652,000 after purchasing an additional 209,667 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of Jazz Pharmaceuticals by 4.2% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 197,174 shares of the specialty pharmaceutical company’s stock worth $24,479,000 after purchasing an additional 7,954 shares during the last quarter. Focus Partners Wealth lifted its position in shares of Jazz Pharmaceuticals by 3.4% during the first quarter. Focus Partners Wealth now owns 4,623 shares of the specialty pharmaceutical company’s stock worth $574,000 after purchasing an additional 154 shares during the last quarter. Finally, Geneos Wealth Management Inc. lifted its position in shares of Jazz Pharmaceuticals by 57.6% during the first quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock worth $47,000 after purchasing an additional 137 shares during the last quarter. 89.14% of the stock is currently owned by institutional investors.

Jazz Pharmaceuticals Price Performance

NASDAQ JAZZ opened at $239.83 on Monday. The company has a debt-to-equity ratio of 0.95, a quick ratio of 1.85 and a current ratio of 2.04. The company has a market capitalization of $15.05 billion, a P/E ratio of -11,985.51, a P/E/G ratio of 0.43 and a beta of 0.27. Jazz Pharmaceuticals has a one year low of $105.00 and a one year high of $243.32. The stock has a 50 day moving average price of $202.44 and a 200-day moving average price of $180.29.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its earnings results on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 EPS for the quarter. The firm had revenue of $1.07 billion during the quarter. Jazz Pharmaceuticals had a return on equity of 14.56% and a net margin of 0.66%. As a group, equities analysts predict that Jazz Pharmaceuticals will post 20.75 EPS for the current fiscal year.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.